Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cytosorbents Corporation - Common Stock (NQ: CTSO )

1.100 -0.060 (-5.17%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 32,628
Open 1.140
Bid (Size) 1.100 (26)
Ask (Size) 1.130 (77)
Prev. Close 1.160
Today's Range 1.090 - 1.150
52wk Range 0.7000 - 1.610
Shares Outstanding 54,679,569
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
The Analyst Verdict: CytoSorbents In The Eyes Of 4 Experts
Via Benzinga
Earnings Scheduled For March 31, 2025
Via Benzinga

Performance

YTD
+19.57%
+19.57%
1 Month
+5.77%
+5.77%
3 Month
+6.80%
+6.80%
6 Month
+4.76%
+4.76%
1 Year
+33.87%
+33.87%

More News

Read More
Insights into CytoSorbents's Upcoming Earnings
Via Benzinga
Expert Outlook: CytoSorbents Through The Eyes Of 7 Analysts
Via Benzinga
Analyst Scoreboard: 5 Ratings For CytoSorbents
Via Benzinga
CytoSorbents Postpones Earnings Release to Allow More Time to Complete Annual Audit Following the Passing of Corporate Controller
From CytoSorbents
Via GlobeNewswire
CytoSorbents to Report Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
From CytoSorbents
Via GlobeNewswire
CytoSorbents Further Strengthens Balance Sheet with Exercise of Previously Announced Series A Right Warrants
From CytoSorbents
Via GlobeNewswire
CytoSorbents Strengthens Balance Sheet with Closing of Oversubscribed Rights Offering
From CytoSorbents
Via GlobeNewswire
CytoSorbents Expands Global Footprint with Opening of New Regional Sales Subsidiary in Dubai
From CytoSorbents
Via GlobeNewswire
Health Care Equipment Supplier CytoSorbents Shares Dip Despite Projected Revenue Growth
Via Benzinga
Topics Supply Chain
Exposures Product Safety Supply Chain
CytoSorbents Reports Preliminary Unaudited Fourth Quarter and Full-Year 2024 Product Revenue
From CytoSorbents
Via GlobeNewswire
Expert Outlook: CytoSorbents Through The Eyes Of 5 Analysts
Via Benzinga
CytoSorbents Rights Offering Begins
From CytoSorbents
Via GlobeNewswire
CytoSorbents to Host Investor Meetings in San Francisco During J.P. Morgan Healthcare Conference Week
From CytoSorbents
Via GlobeNewswire
CytoSorbents Announces Rights Offering
From CytoSorbents
Via GlobeNewswire
CytoSorbents to Participate at the Piper Sandler 36th Annual Healthcare Conference
From CytoSorbents
Via GlobeNewswire
CytoSorbents And Converge Biotech Announce Strategic Partnership to Expand Sepsis and Critical Care Treatment with CytoSorb in India
From CytoSorbents; Converge Biotech
Via GlobeNewswire
CytoSorbents Reports Third Quarter 2024 Financial and Operational Results
From CytoSorbents
Via GlobeNewswire
CytoSorbents Submits Health Canada Medical Device License Application for DrugSorb-ATR Following MDSAP Certification
From CytoSorbents
Via GlobeNewswire
FDA Accepts DrugSorb-ATR De Novo Application To Reduce the Severity of CABG-Related Bleeding Due to Ticagrelor and Initiates Substantive Review
From CytoSorbents
Via GlobeNewswire
CytoSorbents to Report Third Quarter 2024 Operating and Financial Results
From CytoSorbents
Via GlobeNewswire
CytoSorbents Submits DrugSorb-ATR Marketing Application to U.S. FDA to Reduce the Severity of Bleeding in Heart Bypass Surgery Patients on the Blood Thinner Ticagrelor and Provides Business Update
From CytoSorbents
Via GlobeNewswire
CytoSorbents to Present at the H.C. Wainwright 26ᵗʰ Annual Global Investment Conference
From CytoSorbents
Via GlobeNewswire
CytoSorbents Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From CytoSorbents
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.